Search Result

Results for "

Cell-based assays

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) 5-HT Receptor (1) Amine N-methyltransferase (1) Anaplastic lymphoma kinase (ALK) (7) Apoptosis (2) Autophagy (5) c-Met/HGFR (8) Carbonyl Reductase (1) Constitutive Androstane Receptor (1) Dopamine Receptor (1) Drug Metabolite (1) E3 Ligase Ligand-Linker Conjugates (9) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Fatty Acid Synthase (FASN) (1) Fluorescent Dye (4) FXR (1) HCV (3) HCV Protease (3) HDAC (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Methyltransferase (3) Indoleamine 2,3-Dioxygenase (IDO) (1) Isotope-Labeled Compounds (4) Ligands for Target Protein for PROTAC (1) MAGL (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (1) Molecular Glues (2) PARP (1) PD-1/PD-L1 (1) PERK (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PROTACs (3) Ras (3) Reference Standards (6) RIP kinase (1) ROS Kinase (7) SARS-CoV (3) Stearoyl-CoA Desaturase (SCD) (1) STING (1) TAM Receptor (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Trk Receptor (4) VEGFR (1) Virus Protease (1)
By Research Areas:	Cancer (33) Infection (5) Inflammation/Immunology (5) Metabolic Disease (5) Neurological Disease (6)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	CpG ODNs (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50878

Crizotinib Maximum Cited Publications 86 Publications Verification PF-02341066	Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase	Cancer
Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-138696

Zanzalintinib 1 Publications Verification XL092	TAM Receptor c-Met/HGFR VEGFR	Cancer
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC₅₀s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research .

HY-10237

Boceprevir 30+ Cited Publications EBP 520; SCH 503034	HCV Protease HCV SARS-CoV	Infection
Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-110267

DY268 3 Publications Verification	FXR	Metabolic Disease
DY268 is a farnesoid X receptor (FXR) antagonist (IC₅₀=7.5 nM). It inhibits FXR transactivation in a cell-based assay with an IC₅₀ value of 468 nM. DY268 can be used in the study of drug-induced liver injury (DILI) .

HY-50878A

Crizotinib hydrochloride Maximum Cited Publications 86 Publications Verification PF-02341066 hydrochloride	Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase Autophagy	Cancer
Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .

HY-119264

PRLX-93936	Molecular Glues Ras Apoptosis HIF/HIF Prolyl-Hydroxylase	Cancer
PRLX-93936 is a molecular Glues that binds to and reprograms the TRIM21 ubiquitin ligase to degrade nuclear pore complexes. PRLX-93936 binds to TRIM21, forms a ternary complex with TRIM21 and NUP98, and mediates the ubiquitination and proteasomal degradation of NUP98 and other nuclear pore complex proteins. PRLX-93936 induces the loss of short-lived cytoplasmic mRNA transcripts, triggers cancer cell apoptosis (Apoptosis), and inhibits the activated Ras pathway. PRLX-93936 inhibits HIF-1 under hypoxic conditions (IC₅₀ = 0.09 μM in cell-based reporter gene assay). PRLX-93936 suppresses tumor growth in mouse models and improves survival rates in mouse models of multiple myeloma. PRLX-93936 is applicable to research related to pancreatic cancer and multiple myeloma .

HY-151813

NNMT-IN-4	Fluorescent Dye	Cancer
NNMT-IN-4 (compound 38) is a selective, uncompetitive and membrane permeability nicotinamide N-methyltransferase (NNMT) inhibitor with IC₅₀ values of 42 and 38 nM in vitro biochemical and cell-based assays, respectively. NNMT-IN-4 shows favorable PK/PD and safety profiles as well as excellent oral bioavailability and pharmaceutical properties. NNMT-IN-4 can be used as a vivo chemical probe of NNMT .

HY-117427

D5D-IN-326 2 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC₅₀s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .

HY-139504

Gamcemetinib CC-99677	MAPKAPK2 (MK2)	Inflammation/Immunology
Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC₅₀=156.3 nM) and cell based assays (EC₅₀=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1 .

HY-111551

FT113 3 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
FT113 is a potent and orally active fatty acid synthase (FASN) inhibitor, with an IC₅₀ of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC₅₀, 90 nM). FT113 shows anti-proliferative activity, and exhibits anti-cancer activity both in vitro and in vivo .

HY-115510

SPR inhibitor 3 1 Publications Verification SPRi3	Carbonyl Reductase	Inflammation/Immunology
SPR inhibitor 3 (SPRi3) is a potent sepiapterin reductase (SPR) inhibitor. SPR inhibitor 3 (SPRi3) displays high binding affinity to human SPR in a cell-free assay (IC₅₀=74 nM) and efficiently reduces biopterin levels in a cell-based assay (IC₅₀=5.2 μM). SPR inhibitor 3 (SPRi3) reduces neuropathic and inflammatory pain through a reduction of BH4 levels .

HY-112476

PRL-3 Inhibitor I 1 Publications Verification	Phosphatase	Cancer
PRL-3 Inhibitor I is a potent PRL-3 inhibitor with an IC₅₀ of 0.9 μM. PRL-3 Inhibitor I shows a reduced invasion in cell-based assay .

HY-119264A

PRLX-93936 dihydrochloride	Molecular Glues Apoptosis Ras HIF/HIF Prolyl-Hydroxylase	Cancer
PRLX-93936 dihydrochloride is a molecular Glues that binds to and reprograms the TRIM21 ubiquitin ligase to degrade nuclear pore complexes. PRLX-93936 dihydrochloride binds to TRIM21, forms a ternary complex with TRIM21 and NUP98, and mediates the ubiquitination and proteasomal degradation of NUP98 and other nuclear pore complex proteins. PRLX-93936 dihydrochloride induces the loss of short-lived cytoplasmic mRNA transcripts, triggers cancer cell apoptosis (Apoptosis), and inhibits the activated Ras pathway. PRLX-93936 dihydrochloride inhibits HIF-1 under hypoxic conditions (IC₅₀ = 0.09 μM in cell-based reporter gene assay). PRLX-93936 dihydrochloride suppresses tumor growth in mouse models and improves survival rates in mouse models of multiple myeloma. PRLX-93936 dihydrochloride is applicable to research related to pancreatic cancer and multiple myeloma .

HY-129634

TrkA-IN-1	Trk Receptor	Neurological Disease
TrkA-IN-1 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor with an IC₅₀ of 99 nM in a cell-based assay. TrkA-IN-1 has analgesic activity .

HY-112436

PF-6683324 Trk-IN-4	Trk Receptor	Neurological Disease
PF-6683324 (Trk-IN-4) is a potent pan-Trk inhibitor in cell-based assays with IC₅₀s of 1.9 nM, 2.6 nM and 1.1 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .

HY-151193

NNMT-IN-3	Amine N-methyltransferase	Metabolic Disease Cancer
NNMT-IN-3 (Compound 14) is a potent and selective nicotinamide N-methyltransferase (NNMT) inhibitor, with IC₅₀ values of 1.1 nM and 0.4 μM in cell-free and cell-based assays, respectively. NNMT-IN-3 can be used in the research of diseases such as obesity, type 2 diabetes and cancer .

HY-163343

Enpp-1-IN-20	Phosphodiesterase (PDE) STING	Cancer
Enpp-1-IN-20 (Compound 31) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor, with an IC₅₀ of 0.09 nM. Enpp-1-IN-20 has strongest inhibitory activity in the cell-based assay, with an IC₅₀ of 8.8 nM. Enpp-1-IN-20 has significant potency in both ENPP1 inhibition and STING pathway stimulation in vitro. Enpp-1-IN-20 can be used for the research of cancer .

HY-103608

(S,R,S)-AHPC-(C3-PEG)2-C6-Cl VHL Ligand-Linker Conjugates 11; E3 ligase Ligand-Linker Conjugates 11	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-(C3-PEG)2-C6-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-PEG)2-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays .

HY-112495

VH032-PEG5-C6-Cl 2 Publications Verification HaloPROTAC 2	E3 Ligase Ligand-Linker Conjugates	Cancer
VH032-PEG5-C6-Cl (HaloPROTAC 2) is a conjugate of ligands for E3 and 21-atom-length linker. The connector of linker is Halogen group. VH032-PEG5-C6-Cl incorporates the VH032 based VHL ligand and 5-unit PEG linker. VH032-PEG5-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays .

HY-156152A

CARM1 degrader-1 hydrochloride	PROTACs Histone Methyltransferase	Cancer
CARM1 degrader-1 hydrochloride is a CARM1 PROTAC degrader (DC₅₀ = 8.1 nM) with high selectivity over other protein arginine methyltransferases. CARM1 degrader-1 hydrochloride degrades CARM1 in a VHL- and proteasome-dependent manner. CARM1 degrader-1 hydrochloride downregulates the methylation level of CARM1 substrates in cell-based assays. CARM1 degrader-1 hydrochloride inhibits cancer cell migration in cell-based assays. CARM1 degrader-1 hydrochloride can be used in breast cancer research .

HY-111538

MAGL-IN-1 1 Publications Verification	MAGL	Cancer
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC₅₀ of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays .

HY-50878S

Crizotinib-d5 PF-02341066-d₅	Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase Autophagy	Cancer
Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-103606

(S,R,S)-AHPC-PEG6-C4-Cl VH032-PEG6-C4-Cl; VHL Ligand-Linker Conjugates 10; E3 ligase Ligand-Linker Conjugates 9	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG6-C4-Cl is a conjugate of ligands for E3 and 25-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG6-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays .

HY-103605

(S,R,S)-AHPC-C6-PEG3-C4-Cl 1 Publications Verification VH032-C6-PEG3-C4-Cl; VHL Ligand-Linker Conjugates 12; E3 ligase Ligand-Linker Conjugates 8	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C6-PEG3-C4-Cl (VH032-C6-PEG3-C4-Cl) is a conjugate of ligands for E3 and 20-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-C6-PEG3-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays .

HY-G0002

Lurasidone metabolite 14326	Drug Metabolite Dopamine Receptor 5-HT Receptor	Neurological Disease
Lurasidone metabolite 14326 is a minor active metabolite of Lurasidone (HY-B0032A) generated via metabolism by CYP3A4. Lurasidone metabolite 14326 shares similar receptor-binding properties with Lurasidone, acting as an antagonist of the dopamine D2 receptor (dopamine D2 receptor), an antagonist of the serotonin 5-HT2A and 5-HT7 receptors (5-HT2A and 5-HT7 receptor), and a partial agonist of the serotonin 5-HT1A receptor. Lurasidone metabolite 14326 can be used in the research of schizophrenia and bipolar depression .

HY-177617

Bazlitoran IMO-8400	Toll-like Receptor (TLR)	Inflammation/Immunology
Bazlitoran (IMO-8400) is an oligonucleotide-based TLR7/8/9 antagonist. Bazlitoran blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran is associated with injection site reactions. Bazlitoran improves moderate-to-severe plaque psoriasis .

HY-112437

PF-06737007	Trk Receptor	Neurological Disease
PF-06737007 is a potent pan-Trk inhibitor in cell-based assays with IC₅₀s of 7.7 nM, 15 nM and 3.9 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .

HY-156152

CARM1 degrader-1	PROTACs Histone Methyltransferase	Cancer
CARM1 degrader-1 is a CARM1 PROTAC degrader (DC₅₀ = 8.1 nM) with high selectivity over other protein arginine methyltransferases. CARM1 degrader-1 degrades CARM1 in a VHL- and proteasome-dependent manner. CARM1 degrader-1 downregulates the methylation level of CARM1 substrates in cell-based assays. CARM1 degrader-1 inhibits cancer cell migration in cell-based assays. CARM1 degrader-1 can be used for the research of breast cancer .

HY-175250

TNF-α-IN-25	TNF Receptor	Inflammation/Immunology
TNF-α-IN-25 is an orally active TNF-α inhibitor. TNF-α-IN-25 shows Fluorescence Polarization (FP) assay IC₅₀ of 103 nM in FP binding assays and L929 assay IC₅₀ of 505 nM in cell-based assays. TNF-α-IN-25 inhibits paw swelling in the glucose-6-phosphate isomerase (GPI) arthritis model. TNF-α-IN-25 can be used for the study of arthritis .

HY-161352

NPI52	Virus Protease	Infection
NPI52 (Compound E1) is a foot-and-mouth disease virus 3C protease (FMDV 3Cpro) inhibitor, with IC₅₀ values of 0.05 and 0.11 µM in FRET and cell-based assay, respectively .

HY-134811

KRAS G12D inhibitor 1	Ras PERK	Cancer
KRAS G12D inhibitor 1 is a KRAS ^G12D inhibitor with an IC₅₀ value of 0.4 nM. KRAS G12D inhibitor 1 inhibits KRas ^G12D-mediated ERK phosphorylation. KRAS G12D inhibitor 1 can be used for cancer research .

HY-103607

(S,R,S)-AHPC-PEG2-C4-Cl 1 Publications Verification VH032-PEG2-C4-Cl; VHL Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 10	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG2-C4-Cl (VH032-PEG2-C4-Cl) is a conjugate of ligands for E3 and 13-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG2-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based linker. (S,R,S)-AHPC-PEG2-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent PARP inhibitor with K_is of 2 and 5 nM against PARP-2 and PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP activity .

HY-177758

PROTAC HDAC6 degrader 8	PROTACs HDAC	Cancer
HDAC6 degrader-6 (Compound 11b) is a potent and selective HDAC6 PROTAC degrader with a DC₅₀ of 1.9 nM. HDAC6 degrader-6 has no effect on the protein levels of other HDAC family members and does not degrade IKZF1, IKZF3, and GSPT1. HDAC6 degrader-6 can be used to study multiple myeloma (Pink: HDAC6 ligand (HY-177776); Blue: CRBN ligand (HY-W998281); Black: Linker) .

HY-10237R

Boceprevir (Standard) EBP 520 (Standard); SCH 503034 (Standard)	Reference Standards HCV Protease HCV SARS-CoV	Infection
Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-50878AS

Crizotinib-d9 hydrochloride PF-02341066-d9 hydrochloride	c-Met/HGFR Autophagy Anaplastic lymphoma kinase (ALK) ROS Kinase Isotope-Labeled Compounds	Cancer
Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .

HY-179180

PD-1/PD-L1-IN-59	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-59 (Compound MZ51) is a PD-1/PD-L1 inhibitor with an IC₅₀ of 183 nM. PD-1/PD-L1-IN-59 can be used for the study of triple-negative breast cancer (TNBC) .

HY-163520

IDO1-IN-24	Indoleamine 2,3-Dioxygenase (IDO)	Others
IDO1-IN-24 (compound 2c) inhibits IDO1 production in cell-based assay with an IC₅₀ value of 17 μM .

HY-112434

PF-06733804	Trk Receptor	Neurological Disease
PF-06733804 is a potent pan-Trk inhibitor in cell-based assays with IC₅₀s of 8.4 nM, 6.2 nM and 2.2 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .

HY-10555

AMG-221	11β-HSD	Metabolic Disease
AMG-221 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with a K_i of 12.8 nM in vitro biochemical scintillation proximity assay (SPA) and an IC₅₀ of 10.1 nM in cell-based assays . AMG-221 can be used for the research of type 2 diabetes .

HY-10237S

Boceprevir-d9 EBP 520-d₉; SCH 503034-d₉	Isotope-Labeled Compounds HCV Protease HCV SARS-CoV	Infection
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CLpro activity .

HY-110134

S07662	Constitutive Androstane Receptor	Metabolic Disease
S07662 is a human constitutive androstane receptor (hCAR) inhibitor with an IC₅₀ of 0.7 μM. S07662 recruits the corepressor NCoR in cell-based assays and attenuate the expression of CYP2B6 mRNA in human primary hepatocytes induced by phenytoin (HY-B0448) and CITCO (HY-103244) .

HY-D2761

DY-680-NHS ester	Fluorescent Dye	Others
DY-680-NHS ester is an amine reactive hydrophilic fluorochrome. It can be conjugated to an antibody with higher D/P ratio without causing fluorescence quenching and conjugate precipitation, and it is widely used in applications including western blotting, microscopy, flow cytometry, and cell-based assays. The spectrum has an excitation of 690nm and emission at 709nm.

HY-155151

RIPK2/3-IN-1	RIP kinase	Inflammation/Immunology
RIPK2/3-IN-1 is a potent dual RIPK2/3 kinases inhibitor with IC₅₀ values of 3 nM and 117 nM, respectively. RIPK2/3-IN-1 is against RIPK2 with IC₅₀ value 14 nM in 14-TriLAN-Gly/NOD1 THP-1 cell-based NF-κB reporter assay .

HY-50878B

Crizotinib acetate PF-02341066 acetate	Anaplastic lymphoma kinase (ALK) ROS Kinase c-Met/HGFR	Cancer
Crizotinib (PF-02341066) acetate is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib acetate inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib acetate is also a ROS1 inhibitor. Crizotinib acetate has effective tumor growth inhibition .

HY-122038

NU-8165	MDM-2/p53	Cancer
NU-8165 is an inhibitor of the MDM2-p53 protein-protein interaction with anti-tumor activity. Optimization of NU-8165 was guided by MDM2 NMR titrations, which indicated key binding interaction regions. NU-8165 activated MDM2 and p21 transcription in cell-based assays and showed modest selectivity for wild-type p53 cell lines .

HY-50878R

Crizotinib (Standard) PF-02341066 (Standard)	Reference Standards Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase Autophagy	Cancer
Crizotinib (Standard) is the analytical standard of Crizotinib. This product is intended for research and analytical applications. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-W806047

BRD4 Inhibitor-37	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-37 is a compound with anticancer activity that has inhibitory activity against BRD4. BRD4 Inhibitor-37 has an IC50 of approximately 0.05-0.1 μM in binding assays and shows a GI50 of 0.1-0.3 μM in cell-based assays. The effect of BRD4 Inhibitor-37 on c-Myc, a downstream protein of BRD4, has been validated, demonstrating its ability to intervene in this signaling pathway. BRD4 Inhibitor-37 exhibits selectivity among five different bromodomain proteins, enhancing its potential as a BET protein inhibitor .

HY-124305

ML395	Endogenous Metabolite	Infection
ML395 is a potent and selective allosteric inhibitor of phospholipase D2 with antiviral activity. The cellular PLD1 IC50 value of ML395 exceeds 30,000 nM, while its cellular PLD2 IC50 value is 360 nM. ML395 shows excellent pharmacokinetic characteristics in vitro and physiochemical properties superior to other reported phospholipase inhibitors. ML395 shows interesting antiviral activity in cell-based assays against multiple influenza virus strains (H1, H3, H5, and H7) .

HY-50878S2

Crizotinib-d9 PF-02341066-d₉	Isotope-Labeled Compounds	Cancer
Crizotinib-d₉ (PF-02341066-d₉) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

Cat. No.	Product Name

HY-L111

Novel Bioactive Compound Library

2,981 compounds

MCE Novel Bioactive Compound Library consists of 2,981 bioactive compounds with validated bioactivities tested by cell-based assays or biochemical assays. All compounds in this library are structurally novel and bioactivity diverse which makes it easier to discover new lead compounds. MCE Novel Bioactive Compound Library, as a supplement of MCE bioactive compound library (HY-L001), is a useful tool to screen new lead compounds.

Cat. No.	Product Name	Type

HY-D2761

DY-680-NHS ester	Fluorescent Dye
DY-680-NHS ester is an amine reactive hydrophilic fluorochrome. It can be conjugated to an antibody with higher D/P ratio without causing fluorescence quenching and conjugate precipitation, and it is widely used in applications including western blotting, microscopy, flow cytometry, and cell-based assays. The spectrum has an excitation of 690nm and emission at 709nm.

HY-D2736

BP Light 800 NHS ester	Fluorescent Dye
BP Light 800 NHS ester is an amine reactive hydrophilic fluorochrome . It can be conjugated to antibody with higher D/P ratio and widely used applications including western blotting, microscopy, flow cytometry, and cell based assays.

Cat. No.	Product Name	Chemical Structure

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-50878AS

Crizotinib-d9 hydrochloride

Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .

HY-10237S

Boceprevir-d9
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CLpro activity .

HY-50878S2

Crizotinib-d9

Crizotinib-d₉ (PF-02341066-d₉) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-50878S1

Crizotinib-d8

Crizotinib-d₈ (PF-02341066-d₈) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

Cat. No.	Product Name		Classification

HY-134811

KRAS G12D inhibitor 1		Alkynes
KRAS G12D inhibitor 1 is a KRAS ^G12D inhibitor with an IC₅₀ value of 0.4 nM. KRAS G12D inhibitor 1 inhibits KRas ^G12D-mediated ERK phosphorylation. KRAS G12D inhibitor 1 can be used for cancer research .

Cat. No.	Product Name		Classification

HY-177617

Bazlitoran IMO-8400		CpG ODNs
Bazlitoran (IMO-8400) is an oligonucleotide-based TLR7/8/9 antagonist. Bazlitoran blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran is associated with injection site reactions. Bazlitoran improves moderate-to-severe plaque psoriasis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: